We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Genome-Wide cfDNA Analysis Detects Therapy Response in B-Cell Lymphoma

By LabMedica International staff writers
Posted on 10 Nov 2021
Print article
Image: The Bio-Rad QX200 Droplet Digital PCR (ddPCR) reader (Photo courtesy of University of California Santa Barbara)
Image: The Bio-Rad QX200 Droplet Digital PCR (ddPCR) reader (Photo courtesy of University of California Santa Barbara)
Diffuse large B-cell lymphoma (DLBCL) is the most common, aggressive type of non-Hodgkin lymphoma. Although 50% to 60% of individuals achieve cure with chemoimmunotherapy, outcomes are poor for relapsed/refractory disease.

Chimeric antigen receptor (CAR) T-cell therapy represents breakthrough progress in personalized cancer therapy for patients with lymphoma. Low-coverage, genome-wide cell-free DNA measurements commonly used in noninvasive prenatal testing also appear useful in differentiating CAR T-cell therapy responders from non-responders among B-cell lymphoma patients.

Hematologists at the University of California San Diego (La Jolla, CA, USA) enrolled consecutive patients with relapsed/refractory B-cell lymphoma undergoing CAR T-cell therapy. Whole blood was collected from 12 patients undergoing CAR T-cell therapy for relapsed/refractory B-cell lymphoma. Samples were collected on standardized schedule of days. A total of 127 blood samples were processed to plasma and the buffy coat (cellular) component. For each blood sample, a plasma fraction and a buffy coat fraction were retained for subsequent testing. Scientists from Laboratory Corporation of America (Burlington, NC, USA) were part of the study group.

Cell-free DNA (cfDNA) from the plasma of each sample was extracted using a bead-based method. Libraries for genome-wide sequencing were created from cfDNA and sequencing was performed using HiSeq2500 instruments (Illumina, San Diego, CA, USA). Sequencing data were processed, and the genome instability number (GIN) was calculated. Total genomic DNA was extracted from the buffy coat using a column-based method (Qiagen, Venlo, The Netherlands). A ddPCR reaction was designed to quantify the abundance of the CAR construct and the human Ribonuclease P (RNAseP) gene using a QX200 droplet reader (Bio-Rad, Hercules, CA, USA).

The investigators reported that all five patients who remained in complete response (CR) at the time of last measurement had genomic instability number (GIN) <170 (threshold). Two patients who attained CR, but later relapsed, and all but one patient who had best response other than CR had last GIN measurement of >170. In five of six patients with relapsed or progressive disease, increasing GIN was observed prior to the diagnosis by imaging. The abundance of CAR T-cell construct (absolute number of construct copies relative to the number of human genome equivalents) also showed a trend to correlate with outcome by day 10.

Aaron M. Goodman, MD, a professor of medicine and the study's first author, said “This technology is perfect for lymphoma, explaining that cfDNA is an attractive means of monitoring lymphomas, as these cancers behave in some ways like solid tumors and feature cells that are often more sensitive to death and therefore to releasing nucleic acids into the bloodstream.”

The authors concluded that non-invasive liquid biopsy with cfDNA and copy number alterations (CNA) analysis may be correlated with response and may be utilized to monitor response in patients with relapsed B-cell lymphoma treated with CAR T-cell therapy. The study was published on October 13, 2021 in the journal Transplantation and Cellular Therapy.

Related Links:
University of California San Diego
Laboratory Corporation of America

Gold Supplier
SARS-CoV-2 Antigen Test
Actim SARS-CoV-2
KRONUS Glutamic Acid Decarboxylase Autoantibody (GADAb) ELISA Assay Kit
Gold Supplier
Desktop Urine Analyzer

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.